Cover Image
Market Research Report

Chlamydia Infections - Pipeline Review, H2 2018

Published by Global Markets Direct Product code 200439
Published Content info 72 Pages
Delivery time: 1-2 business days
Price
Back to Top
Chlamydia Infections - Pipeline Review, H2 2018
Published: September 26, 2018 Content info: 72 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chlamydia Infections - Pipeline Review, H2 2018, provides an overview of the Chlamydia Infections (Infectious Disease) pipeline landscape.

Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles. Predisposing factors include age, multiple sex partners and history of prior sexually transmitted infection. Treatment includes antibiotics and pain medicine.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chlamydia Infections - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Chlamydia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 1, 10 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.

Chlamydia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chlamydia Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Chlamydia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chlamydia Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chlamydia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chlamydia Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chlamydia Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chlamydia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC10781IDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chlamydia Infections - Overview
    • Chlamydia Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Chlamydia Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Chlamydia Infections - Companies Involved in Therapeutics Development
    • Abera Bioscience AB
    • Abivax SA
    • BlueWillow Biologics Inc
    • Evofem Biosciences Inc
    • Genetic Immunity Inc
    • Lawrence Livermore National Laboratory
    • Lead Discovery Center GmbH
    • Merck & Co Inc
    • Microbiotix Inc
    • Prokarium Ltd
    • QureTech Bio AB
    • SATT IDF Innov SAS
    • Vault Pharma Inc
    • Vaxine Pty Ltd
  • Chlamydia Infections - Drug Profiles
    • Ab-03 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ABX-196 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Amphora - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ChlamyDerm - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia trachomatis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PEG-2S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Inhibit CPAF for Chlamydia Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Chlamydia Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block Virulence for Chlamydia Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit 16S rRNA for Gonorrhea and Chlamydia Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • solithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPI-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chlamydia Infections - Dormant Projects
  • Chlamydia Infections - Product Development Milestones
    • Featured News & Press Releases
      • Apr 20, 2017: New weapon in fight against antibiotic resistance discovered
      • Dec 02, 2015: NanoBio's Chlamydia Vaccine Improves Clearance of Bacteria and Prevents Pelvic Inflammatory Disease in Mice
      • Aug 03, 2015: New Vaccine For Chlamydia to Use Synthetic Biology
      • Aug 03, 2015: SynbiCITE funds new vaccine for Chlamydia
      • Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection
      • Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Chlamydia Infections, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Chlamydia Infections - Pipeline by Abera Bioscience AB, H2 2018
  • Chlamydia Infections - Pipeline by Abivax SA, H2 2018
  • Chlamydia Infections - Pipeline by BlueWillow Biologics Inc, H2 2018
  • Chlamydia Infections - Pipeline by Evofem Biosciences Inc, H2 2018
  • Chlamydia Infections - Pipeline by Genetic Immunity Inc, H2 2018
  • Chlamydia Infections - Pipeline by Lawrence Livermore National Laboratory, H2 2018
  • Chlamydia Infections - Pipeline by Lead Discovery Center GmbH, H2 2018
  • Chlamydia Infections - Pipeline by Merck & Co Inc, H2 2018
  • Chlamydia Infections - Pipeline by Microbiotix Inc, H2 2018
  • Chlamydia Infections - Pipeline by Prokarium Ltd, H2 2018
  • Chlamydia Infections - Pipeline by QureTech Bio AB, H2 2018
  • Chlamydia Infections - Pipeline by SATT IDF Innov SAS, H2 2018
  • Chlamydia Infections - Pipeline by Vault Pharma Inc, H2 2018
  • Chlamydia Infections - Pipeline by Vaxine Pty Ltd, H2 2018
  • Chlamydia Infections - Dormant Projects, H2 2018

List of Figures

  • Number of Products under Development for Chlamydia Infections, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Targets, H2 2018
  • Number of Products by Stage and Targets, H2 2018
  • Number of Products by Mechanism of Actions, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018
Back to Top